Summary & Overview
CPT 0321U: Urinary Tract Infection Detection and Resistance Test
CPT code 0321U designates a proprietary laboratory molecular assay — the Bridge Urinary Tract Infection Detection and Resistance Test from Bridge Diagnostics — that identifies up to 20 specific bacterial or fungal organisms in urine and screens for 16 antibiotic resistance genes. The code matters nationally as molecular diagnostics for urinary tract infections (UTIs) can change diagnostic workflows, influence antibiotic stewardship, and affect reimbursement and coverage policies as labs adopt proprietary panels.
Key payers discussed include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of the clinical purpose of the test, typical service setting, and which payers are addressed. The publication summarizes common billing modifiers and situates the code within laboratory service lines. It also outlines what to expect in policy and coverage reviews for PLA codes, how this test fits into antibiotic-resistance detection efforts, and practical considerations for documentation and claims submission.
This national-oriented summary provides clinicians, laboratory administrators, and billing professionals with the clinical context and payer focus needed to assess adoption implications and prepare for payer-specific policy inquiries and claims processing.
Billing Code Overview
CPT code 0321U is a Proprietary Laboratory Analyses (PLA) code for the Bridge Urinary Tract Infection Detection and Resistance Test from Bridge Diagnostics. The test uses multiple nucleic acid probes to detect any of 20 specific bacterial or fungal organisms in a urine specimen and includes probes for 16 associated antibiotic resistance genes. Results may help clinicians identify the likely causative organism for a urinary tract infection and inform selection of antibiotic therapy or indicate need for further testing.
Service type: Proprietary laboratory molecular diagnostic test (nucleic acid probe panel)
Typical site of service: Clinical laboratory or outpatient laboratory facility
Clinical & Coding Specifications
Clinical Context
A typical patient is an adult woman presenting to an urgent care clinic or primary care office with symptoms suggestive of a urinary tract infection (UTI) such as dysuria, urinary frequency, urgency, suprapubic pain, or hematuria. The clinician collects a clean-catch midstream urine specimen and orders the Bridge Urinary Tract Infection Detection and Resistance Test (0321U) to rapidly identify bacterial or fungal pathogens and associated resistance genes when empiric therapy is uncertain, the patient has recurrent infections, recent antibiotic exposure, complicated urinary anatomy, or risk factors for resistant organisms. The specimen is sent to the performing laboratory; the lab uses multiple nucleic acid probes to detect up to 20 specific organisms and 16 resistance genes. Results are returned to the clinician, who uses organism identification and resistance marker information to refine antibiotic selection, guide the need for urine culture or additional testing, or determine specialist referral. Typical sites of service include outpatient clinics, urgent care centers, emergency departments, and independent clinical laboratories. The service type is laboratory molecular diagnostic testing (Proprietary Laboratory Analyses).
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
00 | Default/No modifier | Use when no specific modifier applies to the billed service. |
26 | Professional component | Use if the professional interpretation component is billed separately from the technical component. |
TC | Technical component | Use when billing only the technical component of the laboratory test (instrumentation and analysis). |
52 | Reduced services | Use if the test was partially performed or interrupted and a reduced service reportable value is appropriate. |
53 | Discontinued procedure | Use if specimen processing was started but discontinued for documented clinical reasons. |
59 | Data not provided in input | Data not available in the input. |
QK | Medical direction of two or more technicians | Use when supervising multiple technicians in performance of complex in‑lab testing (CMS Q modifiers context for certain services). |
QX | Modifier for auxiliary personnel | Use when services involve an auxiliary personnel arrangement under applicable payor rules. |
QY | Medical direction of one technician | Use when the physician directs a single technician performing the test under applicable rules. |
SH | Digital health service furnished; synchronous | Use if testing is part of a synchronous telehealth consultation where modifier is applicable by payor policy. |
SJ | Non‑secure synchronous telemedicine | Use if applicable by payor policy when test ordering/performance is associated with telemedicine services. |
22 | Increased procedural services | Use when test required substantially greater resources than typical and documentation supports increased complexity. |
80 | Assistant surgeon | Not typically applicable to laboratory testing; included when assistant billing is relevant in combined procedural encounters. |
| Taxonomy Code | Specialty | Notes |
|---|---|---|
| 208100000X | Family Medicine | Primary care clinicians ordering UTI diagnostics and managing initial treatment. |
| 207Q00000X | Emergency Medicine | ED physicians ordering rapid molecular UTI tests for acute presentations. |
| 207L00000X | Pathology & Laboratory Medicine | Laboratory directors and pathologists overseeing test performance and interpretation. |
| 207R00000X | Infectious Disease | Specialists who may use molecular resistance results to guide complex therapy. |
| 282N00000X | Urology | Urologists managing recurrent/complicated UTIs and interpreting pathogen/resistance data. |
Related Diagnoses
| ICD-10 Code | Description | Clinical Relevance |
|---|---|---|
N39.0 | Urinary tract infection, site not specified | Primary indication for ordering 0321U to identify causative organisms and resistance markers. |
N30.90 | Cystitis, unspecified without hematuria | Lower urinary tract infection presentation commonly evaluated with this molecular test. |
N10 | Acute tubulo-interstitial nephritis | Considered when UTI symptoms with renal involvement prompt pathogen identification and resistance testing. |
N12 | Tubulo-interstitial nephritis, not specified as acute or chronic | Relevant for atypical or complicated infections where targeted molecular testing assists diagnosis. |
N39.0A | Urinary tract infection, recurrent (note: fictive placeholder) | Data not available in the input. |
R30.0 | Dysuria | Symptom code often accompanying UTI evaluation and may prompt ordering of the test. |
O23.6 | Urinary tract infection in pregnancy, unspecified | Pregnancy-associated UTIs require careful organism and resistance identification to guide safe therapy. |
N39.3 | Stress urinary incontinence (excluded diagnosis often considered) | Not a direct indication but may be part of differential when evaluating urinary symptoms. |
Related CPT Codes
| CPT Code | Description | Relationship to This Procedure |
|---|---|---|
87086 | Culture, bacterial; quantitative colony count, urine | Often ordered when molecular detection identifies an organism to obtain organism quantitation and full susceptibility testing. |
87088 | Culture, bacterial; urine, bacterial isolation, simple | May be performed alongside or after molecular testing to isolate organisms for phenotypic susceptibility testing. |
87471 | Infectious agent detection by nucleic acid (DNA or RNA), direct probe(s); Chlamydia trachomatis, amplified probe technique | Example of targeted molecular testing; illustrates other NAATs commonly performed on urine specimens when STI causes are considered. |
87490 | Infectious agent detection by nucleic acid (DNA or RNA), multiple organisms, amplified probes, multiplex; each additional organism (list separately in some contexts) | Represents multiplex NAAT methodologies related to pathogen panels and comparable to multiplex molecular UTI panels. |
83891 | Drug resistance gene analysis, molecular assay (example generic code for resistance genes) | Represents molecular resistance testing typically coordinated with organism ID to inform therapy (use of proprietary PLA 0321U replaces generic codes for this specific test). |